CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 41 enrolled
Drug / intervention
Pegyinterferon-alfa-2adrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02068365
NCT02068365Phase 4Completed
CompareCT.gov

An Open-label Trial of 48-week Peginterferon Alfa-2a (PEGASYS) to Assess the Sustained Response of Chronic Hepatitis B Patients With HBeAg Seroconversion on Nucleot(s)Ide Analogue Therapy

Chinese University of Hong Kong·interventional·Posted Feb 21, 2014·Updated Jul 31, 2019

In Brief

A Phase 4 clinical trial evaluating Pegyinterferon-alfa-2a for Chronic Hepaititis B. Completed, enrolled 41 participants across 1 site.

Detailed Summary

This is a multi-center, single-arm, open-label study on the virological response of chronic HBV infection to pegyinterferon-alfa-2a among patients who achieved HBeAg seroconversion on nucleos(t)ide analogue (NA) treatment. The primary endpoint of this study is to investigate the sustained response (HBeAg seroconversion with HBV DNA \<2000 IU/ml) to peginterferon at 24 weeks after the end of treatment.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsChronic Hepaititis B
CountriesHong Kong
Collaborators--

Timeline

Phase 4CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedFeb 21, 2014
Enrollment StartJun 1, 2013
Primary CompletionJun 1, 2019
TodayJul 2, 2026
Enrollment to primary: 6 yearsPosted 12.4 years ago

Interventions

Pegyinterferon-alfa-2adrug

Pegyinterferon-alfa-2a 180mcq weekly for 48 weeks